Clinical Trials and Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…

In Canada, an active 66-year-old man with no signs or symptoms of heart failure is diagnosed with atrial fibrillation after experiencing several weeks of…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…

OverviewISAP examines the effects of oral semaglutide, a glucagon-like protein-1 receptor agonist used for diabetes, on the build-up of proteins in the brain…

A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino…

The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along…

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…

CARLSBAD, Calif., April 24, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Incexternal link, opens in a new tab. (Nasdaq: IONSexternal link, opens in a new tab) today…

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an…

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…